Your browser doesn't support javascript.
loading
Digital tools for the assessment of pharmacological treatment for depressive disorder: State of the art.
Van Assche, Evelien; Antoni Ramos-Quiroga, J; Pariante, Carmine M; Sforzini, Luca; Young, Allan H; Flossbach, Yanina; Gold, Stefan M; Hoogendijk, Witte J G; Baune, Bernhard T; Maron, Eduard.
Afiliação
  • Van Assche E; Department of Psychiatry, University of Münster, Münster, Germany. Electronic address: Evelien.vanassche@uni-muenster.de.
  • Antoni Ramos-Quiroga J; Department of Psychiatry, Hospital Universitari Vall d'Hebron (HUVH), Barcelona, Catalonia, Spain; Department of Psychiatry and Forensic Medicine, Universitat Autònoma de Barcelona, Barcelona, Catalonia, Spain; Group of Psychiatry, Mental Health and Addictions, Vall d'Hebron Research Institute (VHIR
  • Pariante CM; King's College London, Institute of Psychiatry, Psychology and Neuroscience, Department of Psychological Medicine, London, UK; National Institute for Health Research Mental Health Biomedical Research Centre, South London and Maudsley NHS Foundation Trust and King's College London, London, UK.
  • Sforzini L; King's College London, Institute of Psychiatry, Psychology and Neuroscience, Department of Psychological Medicine, London, UK.
  • Young AH; King's College London, Institute of Psychiatry, Psychology and Neuroscience, Department of Psychological Medicine, London, UK; National Institute for Health Research Mental Health Biomedical Research Centre, South London and Maudsley NHS Foundation Trust and King's College London, London, UK.
  • Flossbach Y; Neuroscience, Global Drug Development, Novartis Pharma AG, Basel, Switzerland.
  • Gold SM; Charité - Universitätsmedizin Berlin, Department of Psychiatry and Psychotherapy, Campus Benjamin Franklin, Berlin, Germany; Charité - Universitätsmedizin Berlin, Department of Psychosomatic Medicine, Campus Benjamin Franklin, Berlin, Germany; University Medical Center Hamburg-Eppendorf, Institute o
  • Hoogendijk WJG; Department of Psychiatry, Erasmus University Medical Centre, Rotterdam, the Netherlands.
  • Baune BT; Department of Psychiatry, Melbourne Medical School, The University of Melbourne, Melbourne, Australia; The Florey Institute of Neuroscience and Mental Health, The University of Melbourne, Parkville, VIC, Australia.
  • Maron E; Department of Psychiatry, University of Tartu, Tartu, Estonia; Faculty of Medicine, Department of Medicine, Centre for Neuropsychopharmacology, Division of Brain Sciences, Imperial College London, London, UK; Documental Ltd, Tallin, Estonia; West Tallinn Central Hospital, Tallinn, Estonia.
Eur Neuropsychopharmacol ; 60: 100-116, 2022 07.
Article em En | MEDLINE | ID: mdl-35671641
ABSTRACT
Depression is an invalidating disorder, marked by phenotypic heterogeneity. Clinical assessments for treatment adjustments and data-collection for pharmacological research often rely on subjective representations of functioning. Better phenotyping through digital applications may add unseen information and facilitate disentangling the clinical characteristics and impact of depression and its pharmacological treatment in everyday life. Researchers, physicians, and patients benefit from well-understood digital phenotyping approaches to assess the treatment efficacy and side-effects. This review discusses the current possibilities and pitfalls of wearables and technology for the assessment of the pharmacological treatment of depression. Their applications in the whole spectrum of treatment for depression, including diagnosis, treatment of an episode, and monitoring of relapse risk and prevention are discussed. Multiple aspects are to be considered, including concerns that come with collecting sensitive data and health recordings. Also, privacy and trust are addressed. Available applications range from questionnaire-like apps to objective assessment of behavioural patterns and promises in handling suicidality. Nonetheless, interpretation and integration of this high-resolution information with other phenotyping levels, remains challenging. This review provides a state-of-the-art description of wearables and technology in digital phenotyping for monitoring pharmacological treatment in depression, focusing on the challenges and opportunities of its application in clinical trials and research.
Assuntos
Palavras-chave

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Transtorno Depressivo Limite: Humans Idioma: En Revista: Eur Neuropsychopharmacol Ano de publicação: 2022 Tipo de documento: Article

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Transtorno Depressivo Limite: Humans Idioma: En Revista: Eur Neuropsychopharmacol Ano de publicação: 2022 Tipo de documento: Article